BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Blogs » BioWorld Perspectives » Venter, Watson Warm Up for Clash of the Titans

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / EMA

Venter, Watson Warm Up for Clash of the Titans

July 10, 2012
By Cormac Sheridan

DUBLIN ‑ Europe's biggest scientific carnival is pitching its tent beside the River Liffey this week. Dublin is playing host to the Euroscience Open Forum (ESOF) 2012 meeting and, thereby, assumes the mantle of Europe's City of Science for the year.

Conceived as Europe's answer to the annual meeting of the American Association for the Advancement of Science, ESOF has become an increasingly visible element in Europe's efforts to foster a shared scientific identity. Although different European countries have vastly differing scientific heritages, their scientific futures are converging, thanks to an increasing level of recognition, both in Brussels and across the continent, that the region can only compete on a global basis if it acts in concert.

Ireland's bid to host the event was originally conceived as its coming of age as a location for high quality scientific research, following an expansive strategy that began just over a decade ago. At present, however, the mood is not entirely celebratory. The present government's commitment to open-ended, blue-skies research has wavered, following a catastrophic banking collapse in 2008, which culminated in the country entering a bailout program administered by the International Monetary Fund and the European Central Bank. Although funding for science has held up, just about, a recent sharp turn to a more industrially focused research agenda has been met with anger and dismay by some of the country's leading scientists.

Even so, there will be plenty to celebrate in Dublin this week ‑ in terms of both homegrown successes and the very best of international science. The recent (apparent) detection of the Higgs boson at CERN, in Geneva, will provide one important focus for the meeting. CERN's director general Rolf Heuer will be in town. But the physicists will have to share the limelight with a clutch of heavyweights from the life sciences world, including Nobel laureates Jules Hoffman (2011), Peter Doherty (1996), Torsten Niels Wiesel (1981) and James Watson (1962).

One event of interest to both camps will be Craig Venter's What is Life lecture at Trinity College Dublin on Thursday evening. This will commemorate the original 1943 lecture series by Erwin Schroedinger, one of the founders of quantum mechanics, who spent 14 years in Dublin during and after the Second World War. Schroedinger's book of the same name, which appeared in 1944, was a key text in the early development of molecular biology and a source of inspiration for James Watson and Francis Crick. Watson will be on hand to respond to Venter's address. It might be an exaggeration to dub the event Clash of the Titans, but it's an intriguing prospect nonetheless.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing